Results 11 to 20 of about 19,412 (203)

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report [PDF]

Respiratory Medicine Case Reports, 2017
Pulmonary embolism (PE) can be life-threatening, and it is challenging to diagnose because of its nonspecific signs and symptoms. PE is also an important potential risk of osimertinib treatment, however, clinical courses regarding retreatment after ...
Takayuki Shiroyama, Manabu Hayama, Shingo Satoh, Shingo Nasu, Ayako Tanaka, Satomu Morita, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Tomonori Hirashima   +9 more
doaj   +2 more sources

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC

ESMO Real World Data and Digital Oncology
Background: Osimertinib has been the standard of care in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We evaluated outcomes between osimertinib and first/second-generation (1G/2G) EGFR-tyrosine kinase inhibitors ...
Y. Uehara, Y. Takeyasu, T. Yoshida, A. Tateishi, M. Torasawa, Y. Hosomi, K. Masuda, Y. Shinno, Y. Matsumoto, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe   +13 more
doaj   +2 more sources

Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib

, 2022
Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for treating non-small-cell lung cancer (NSCLC) with EGFR mutations.
1025489, 1025488, 1025487, 1025486, Ogawa, Kazuma, Effendi, Nurmaya, Mishiro, Kenji, Makino, Akira, Ryuichi, Nishii, Nishii, Ryuichi, Fuchigami, Takeshi, Kinuya, Seigo, Kiyono, Yasushi, 1025481, Sawazaki, Izumi, 1025485, 1025484, 1025483, 1025482, Taki, Junichi, Shiba, Kazuhiro, Sofuku, Tomoki, Sudo, Hitomi, 1025492, 1025491, 1025490, Hitomi, Sudo, 1025495, 1025494, 1025493   +29 more
core   +3 more sources

Mitochondrial Morphology Dynamics Remodel Metabolism and Affect TKI Sensitivity in EGFR-Mutated Lung Cancer. [PDF]

Cancer Sci
TKI treatment promotes mitochondrial fission and metabolic reprogramming toward oxidative phosphorylation in residual EGFR‐mutant lung cancer cells. Targeting this metabolic vulnerability restores TKI sensitivity and provides a promising strategy to overcome acquired resistance.
Zhao Y, Liu Y, Xie M, Ye Z, Huang H, Yao M, Zhou F, Zhao J, Tang J.   +8 more
europepmc   +2 more sources

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab. [PDF]

, 2023
BACKGROUND: Osimertinib has emerged as an important tool in the treatment of non-small cell lung cancers (NSCLC) with certain activating mutations of epidermal growth factor receptor (EGFR).
Ou, Sai-Hong, Smith, Janellen, Lopez, Michael, Demirdag, Yesim, Doan, Linda, Hagopian, Garo, Nagasaka, Misako, Rojek, Nathan, Lee, Benjamin   +8 more
core   +1 more source

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report

, 2022
Introduction: EGFR L747P mutations occur rarely, with limited preclinical research and case reports suggesting resistance to osimertinib. Main Concerns, Important Clinical Findings, Primary Diagnoses, Interventions, Outcomes: An 84-year-old white male ...
Gagan, J, Mayer, M, Gerber, DE, von Itzstein, MS   +3 more
core   +1 more source

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

BMC Cancer, 2023
Background Conquering acquired resistance to osimertinib remains a major challenge in treating patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Thus, we aimed to determine the safety and efficacy
Satoru Miura, Yasuhiro Koh, Koichi Azuma, Hiroshige Yoshioka, Kenichi Koyama, Shunsuke Teraoka, Hidenobu Ishii, Kayoko Kibata, Yuichi Ozawa, Takaaki Tokito, Jun Oyanagi, Toshio Shimokawa, Takayasu Kurata, Nobuyuki Yamamoto, Hiroshi Tanaka   +14 more
doaj   +1 more source

Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels

Frontiers in Pharmacology, 2023
Introduction: As the third generation of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), osimertinib has demonstrated more significant cardiotoxicity than previous generations of EGFR-TKIs.
Peiwen Li, Xiaohui Tian, Gongxin Wang, Enshe Jiang, Yanming Li, Guoliang Hao   +5 more
doaj   +1 more source

Supplementary Material for: Successful rechallenge with osimertinib following osimertinib-induced ventricular tachycardia: A case report

, 2023
Osimertinib, a third-generation tyrosine kinase inhibitor, is the first-line treatment for metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor mutations.
Oi I. (17099524), Mio T. (17099530), Tachibana H. (11335818), Saito Z. (17099518), Kanai O. (17099527), Imakita T. (17099521), Ito T. (3760507), Fujita K. (4132615)   +7 more
core   +1 more source